Antiplatelet and anticoagulant drugs do not affect visual acuity in the comparing bevacizumab to ranibizumab in age-related macular degeneration (BRAMD) trial

被引：0
|
作者：
Schauwvlieghe, A. M. E. [1 ]
Buitendijk, G. H. S. [1 ]
Dijkman, G. [1 ]
Hoyng, C. [1 ]
Hooymans, J. M. [1 ]
Verbraak, F. D. [1 ]
Vingerling, J. R. [1 ]
Claver, C. C. [1 ]
Schlingemann, R. O. [1 ]
机构：
[1] Acad Med Ctr, Amsterdam, Netherlands
来源：
ACTA OPHTHALMOLOGICA | 2017年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：22 / 23
页数：2
相关论文
共 50 条
  • [1] Antiplatelet and anticoagulant drugs do not affect visual acuity in neovascular age-related macular degeneration. The BRAMD Study
    Buitendijk, Gabrielle H. S.
    Schauwvlieghe, Ann-Sofie M.
    Vingerling, Johannes R.
    Schlingemann, Reinier
    Klaver, Caroline
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [2] Antiplatelet and Anticoagulant Drugs Do Not Affect Visual Outcome in Neovascular Age-Related Macular Degeneration in the BRAMD Trial
    Buitendijk, Gabrielle H. S.
    Schauwvlieghe, Ann-Sofie M. E.
    Vingerling, Johannes R.
    Schlingemann, Reinier O.
    Klaver, Caroline C. W.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2018, 187 : 130 - 137
  • [3] Ranibizumab versus Bevacizumab in the Netherlands: Comparing the Efficacy of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration - The BRAMD Study
    Schauwvlieghe, A. M. E.
    Dijkman, G.
    Hooymans, J. M.
    Verbraak, F. D.
    Hoyng, C. B.
    Dijkgraaf, M. G. W.
    Peto, T.
    Zwinderman, A. H.
    Vingerling, J. R.
    Schlingemann, R. O.
    OPHTHALMOLOGICA, 2013, 230 : 2 - 3
  • [4] Infographic: Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration: the BRAMD study
    Yusuf, Imran H. H.
    Henein, Christin
    Sivaprasad, Sobha
    EYE, 2024, 38 (SUPPL 2) : 41 - 42
  • [5] Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study
    Schauwvlieghe, A. M. E.
    Dijkman, G.
    Hooymans, J. M.
    Verbraak, F. D.
    Hoyng, C. B.
    Dijkgraaf, M. G. W.
    Peto, T.
    Vingerling, J. R.
    Schlingemann, R. O.
    PLOS ONE, 2016, 11 (05):
  • [6] Analyses Comparing Visual Acuity Between Ranibizumab and Bevacizumab in the Comparison of Age-Related Macular Degeneration Treatments Trials
    Ying, Gui-Shuang
    Maguire, Maureen G.
    JAMA OPHTHALMOLOGY, 2015, 133 (06) : 726 - 726
  • [7] Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration
    Feng, Xue-Feng
    Constable, Ian J.
    McAllister, Ian L.
    Isaacs, Timothy
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2011, 4 (01) : 85 - 88
  • [8] Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration
    Ian J Constable
    Ian L McAllister
    Timothy Isaacs
    International Journal of Ophthalmology, 2011, (01) : 85 - 88
  • [9] The effects of aflibercept following bevacizumab or ranibizumab on visual acuity and central macular thickness in patients with age-related macular degeneration
    Faridi, Ambar
    Shippey, Loton
    Hwang, Thomas
    Lauer, Andreas
    Bailey, Steven
    Flaxel, Christina
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [10] Intravitreal Bevacizumab for Age-Related Macular Degeneration with Good Visual Acuity
    Takahashi, Maki
    Sato, Taku
    Kishi, Shoji
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2010, 54 (06) : 565 - 570
12345